Amerant (AMTB) Q4 2025 Earnings Transcript

Amerant Bancorp reported Q4 diluted EPS of $0.07 versus $0.35 last quarter as noninterest expense jumped to $106.8 million and ROA/ROE fell to 0.10%/1.12%. Balance sheet size shrank, with assets down to $9.8 billion, deposits down 6.2%, and NIM compressing to 3.78%, though CET1 improved to 11.8% and management reiterated 2026 targets of 7%-9% loan growth, 3.65%-3.70% NIM, and a path toward a 1% ROA and 60% efficiency ratio. The call was also notable for restructuring actions, buybacks, an AI efficiency initiative, and early-stage Venezuela deposit growth opportunities.

Analysis

AMTB is in a classic reset phase where reported earnings are being intentionally depressed to cleanse the balance sheet and rebase the franchise. The important second-order effect is that management has effectively chosen to trade near-term ROE for lower funding cost, cleaner credit optics, and a smaller capital denominator; if executed, that can mechanically lift returns even before loan growth meaningfully re-accelerates. The market should focus less on the headline earnings drop and more on whether the criticized book actually rolls off faster than new inflows over the next 2-3 quarters.

The biggest hidden swing factor is expense normalization. If the company really gets to the mid/high-$60mm quarterly run-rate by late 2026, the earnings leverage is substantial because every $1mm of cost reduction flows directly through a relatively modest revenue base. That said, the path is not linear: credit remediation plus selective growth usually creates a lag where provision stays elevated while revenue is still capped by balance-sheet resizing, so the stock can remain range-bound until there is visible evidence of stable loan production without new migrations.

The Venezuela angle is an optionality trade, not a core thesis. If oil-related normalization in that market improves deposit stickiness and AUM flows, the upside is fee income and cheaper, more relationship-based funding—not aggressive loan growth—so the real benefit is a richer mix and lower cost of funds over time. But that opportunity is highly path-dependent and could easily remain narrative-only for several quarters, which argues for treating it as upside convexity rather than underwriting it into base-case valuation.

Contrarian view: the market may be over-penalizing the quarter because a large part of the earnings miss appears self-inflicted and reversible, while the stock is already priced closer to a damaged-bank multiple than a normalized-earnings multiple. The real risk is that asset-quality cleanup reveals more embedded weakness than management expects, forcing more reserve build just as the balance sheet is re-levered. If that happens, the apparent capital strength becomes less of a cushion and more of a trap, because buybacks/dividends would then be funding optics rather than real compounding.

Key Decisions for Investors

• Long AMTB on weakness over the next 1-3 months only if the stock de-risks toward tangible book discount levels that imply little credit improvement; target a rebound if Q1/Q2 shows criticized-loan runoff and normalized expenses trending toward the $67-$68mm run-rate.
• Avoid outright long AMTB into the next print if you need near-term earnings momentum; the cleanest catalyst is a visibly lower migration rate in criticized assets, not revenue growth, so patience is warranted until the next two quarters confirm the cleanup.
• Pair trade: long a higher-quality regional bank with stable credit and operating leverage vs short AMTB for the next 1-2 quarters if you expect the market to continue rewarding cleaner earnings profiles; AMTB is the lower-conviction leg until expense normalization is proven.
• Optionality trade: small speculative long-dated call position in AMTB 2027 or 2028 calls, financed against downside-defined stock exposure, to express the thesis that ROA approaches 1% and efficiency moves toward 60% without paying full equity risk up front.
• If AMTB rallies sharply before evidence of credit stabilization, fade the move; the stock still has event risk from reserve pressure and additional non-core charges, so upside without confirmation is vulnerable to multiple compression.